SCHEMBL17447404

SCHEMBL17447404

COC(=O)/C=C/CNC(=O)c1c[nH]c2ccc(OC(F)(F)F)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 7/20 0.48
NR4A2 P43354 1/20 0.47
HTR4 Q13639 3/20 0.46
DRD2 P14416 2/20 0.46
DRD3 P35462 2/20 0.46
LMNA P02545 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PYGL P06737 1/20 0.44
ROCK2 O75116 1/20 0.44
ROCK1 Q13464 1/20 0.44
MEN1 O00255 1/20 0.43
MITF O75030 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MTNR1A P48039 1/20 0.41
CYP2C8 P10632 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17438030 0.88 NR4A2 (0.58) NR4A2HTR4DRD2DRD3LMNA
SCHEMBL17445857 0.81 NHERF1 (0.55) NR4A2HTR4DRD2DRD3LMNA
SCHEMBL17447381 0.80 MAPT (0.56) NR4A2HTR4DRD2DRD3LMNA
SCHEMBL5331992 0.79 NR4A2 (0.74) TRPV1NR4A2HTR4LMNAMEN1
SCHEMBL17447392 0.78 KDM4E (0.43) HTR4DRD2DRD3LMNAKDM4E
SCHEMBL30644860 0.75 NR4A2 (0.56) TRPV1NR4A2LMNAKDM4EHSD17B10
SCHEMBL12480777 0.75 NR4A2 (0.56) TRPV1NR4A2LMNAKDM4EHSD17B10
SCHEMBL31375050 0.75 NR4A2 (0.55) TRPV1NR4A2LMNAKDM4EMEN1
SCHEMBL28182662 0.74 LMNA (0.56) TRPV1NR4A2LMNAMEN1MITF
SCHEMBL17447402 0.74 MTNR1A (0.50) NR4A2HTR4DRD2DRD3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273208-B2 Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods NORTHWESTERN UNIVERSITY (US) 2019-04-30 US disclosed
US-20170152228-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NORTHWESTERN UNIVERSITY (US) 2017-06-01 US disclosed
US-9586890-B2 Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods NORTHWESTERN UNIVERSITY (US) 2017-03-07 US disclosed
US-20160016893-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NORTHWESTERN UNIVERSITY (US) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152228-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NEDD4, STUB1, CUL1 TRPV1 3992/4885NR4A2 3702/4885HTR4 4536/4885
US-20160016893-A1 SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS NEDD4, STUB1, UBQLN1 TRPV1 2805/4885NR4A2 1943/4885HTR4 3915/4885
US-10273208-B2 Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods NEDD4, STUB1, CUL1 TRPV1 3992/4885NR4A2 3702/4885HTR4 4536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.